On-Sight Interviews

LacriPen Writing Exciting Script for Founders

By Tom Salemi | December 1, 2015

Interview

Read More

Opthea Taking New Approach to Combat Wet AMD

By Mario Admin | December 1, 2015

Megan Baldwin, PhD, Managing Director and CEO of Opthea, gives an update on OPT-302, a soluble receptor consisting of the first three extracellular domains of…

Read More

Ocular Therapeutix Taking Aim at Allergy Market

By Tom Salemi | November 30, 2015

Amar Sawhney, PhD, Chairman, Chairman, President & CEO of Ocular Therapeutics, touts the performance of Dextenza, the company’s anti-allergy medication. Instead of taking one drop…

Read More

`Mythbuster’ Cheskin on Powervision’s Future Pipeline, Strength of IOLs

By Tom Salemi | November 30, 2015

Barry Cheskin, co-founder, president, and CEO of PowerVision, introduces the company’s next iteration, Fluidvision 2020, a new IOL that doubles the power of accommodation for…

Read More

Novaliq Goes After Dry Eye Disease

By Tom Salemi | November 30, 2015

Bernhard Gunther, CEO of Novaliq GmbH, delivers an update on the progress of his compay’s drug delivery pipeline. Novaliq develops innovative pharmaceutical formulations based on…

Read More

MicroOptx Pursues New MIGS Approach

By Tom Salemi | November 30, 2015

Chris Pulling, CEO of MicroOptx, tells OISTV about its Brown Glaucoma Implant (new name pending). The implant is used to lower IOP by draining aqueous…

Read More

Orca Aggressively Pursues Cataract Surgery Market

By Tom Salemi | November 30, 2015

Yariv Bar-On, CEO of Orca Surgical, explains how his company is trying to change how surgeons remove the corneal epithelium during ophthalmic laser surgery. Orca…

Read More

Tarantino on How AcuFocus Found Success Rolling Out KAMRA

By Tom Salemi | November 30, 2015

Acufocus’ Nick Tarantino, Chief Global Clinical Research & Regulatory Affairs Officer, explains how AcuFocus is taking a “nice and measured” approach to rolling out its…

Read More

Exploring Novartis’ Interest in Medtech

By Tom Salemi | November 30, 2015

Reza Zadno, PhD, EIR at InterWest Partners explains his new role at the Novartis Venture Fund. He’ll advise the pharma company on where to commit…

Read More

Aura’s CEO Describes the Challenges of Ocular Melanoma

By Tom Salemi | November 30, 2015

Elisabet “Eli” de los Pinos founded Aura Biosciences in 2009 to chase down innovative treatments for cancer. AURA, which made its first presentation at OIS…

Read More

Oculeve’s Ackermann Talks Allergan

By Tom Salemi | November 30, 2015

Michael Ackermann, CEO of start-up Oculeve, gives an update on his work with Allergan following the purchase of his company and its Dry Eye device.…

Read More

IOPtima Getting Traction in Europe, Asia

By Tom Salemi | November 30, 2015

IOPtima CEO Ronan Castro gives OISTV an update on the company’s commerical launch of the IOPtimate system in Europe and Asia, including operations in China…

Read More

SUBSCRIBE TO OIS NEWS

Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.

We respect your privacy and promise to never send you spam.

Something went wrong. Please check your entries and try again.